• Kura Oncology reported third-quarter 2026 KOMZIFTI net product revenue of $13.9 million, up 53% from the previous quarter.
• A roughly 40-patient darlifarnib registrational trial in HRAS-mutant salivary gland cancer is planned for the first half of 2027, targeting full approval.
• Cash, cash equivalents and short-term investments totaled $492.1 million as of September 30, 2026.
• Additional funding includes $180 million in anticipated Kyowa Kirin milestone payments and up to $300 million potentially available under the Oberland agreement.
• Expected cash resources would support operations beyond initial pivotal Phase 3 KOMET-017 topline results, anticipated in 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kura Oncology Inc. published the original content used to generate this news brief on November 10, 2026, and is solely responsible for the information contained therein.